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Yu Y-L, Thijs L, Saenen N, Melgarejo JD, Wei D-M, Yang W-Y, Yu C-G, Roels HA, Nawrot TS, Maestre GE, Staessen JA, Zhang
Z-Y. Two-year neurocognitive responses to first occupational lead exposure. Scand J Work Environ Health – online first.
doi:10.5271/sjweh.3940

Objectives Lead exposure causes neurocognitive dysfunction in children, but its association with neurocogni-

tion in adults at current occupational exposure levels is uncertain mainly due to the lack of longitudinal studies.
In the Study for Promotion of Health in Recycling Lead (NCT02243904), we assessed the two-year responses
of neurocognitive function among workers without previous known occupational exposure newly hired at lead
recycling plants.

Methods Workers completed the digit-symbol test (DST) and Stroop test (ST) at baseline and annual follow-up

visits. Blood lead (BL) was measured by inductively coupled plasma mass spectrometry (detection limit 0.5 µg/
dL). Statistical methods included multivariable-adjusted mixed models with participants modelled as random
effect.

Results DST was administered to 260 participants (11.9% women; 46.9%/45.0% whites/Hispanics; mean age

29.4 years) and ST to 168 participants. Geometric means were 3.97 and 4.13 µg/dL for baseline BL, and 3.30
and 3.44 for the last-follow-up-to-baseline BL ratio in DST and ST cohorts, respectively. In partially adjusted
models, a doubling of the BL ratio was associated with a 0.66% [95% confidence interval (CI) 0.03–1.30%;
P=0.040] increase in latency time (DST) and a 0.35% (95% CI ‑1.63–1.63%; P=0.59) decrease in the inference
effect (ST). In fully adjusted models, none of the associations of the changes in the DST and ST test results with
the blood lead changes reached statistical significance (P≥0.12).

Conclusions An over 3-fold increase in blood lead over two years of occupational exposure was not associated
with a relevant decline in cognitive performance.

Key terms digit-symbol test; neurocognitive function; occupational exposure; Stroop test.

Lead is a ubiquitous environmental toxicant. The Global
Burden of Disease study assumed a causal association between intellectual disability and lead exposure
in children (1), mainly justified by a participant-level
meta-analysis involving 1333 children enrolled in seven

population-based studies and followed up from birth
or infancy until 5–10 years of age (2). The IQ point
decrements associated with blood lead increments from
2.4–10, 10–20, and 20–30 μg/dL were 3.9, 1.9, and
1.1, respectively (2). The lead-associated intellectual
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decrement in children with a maximal blood lead level
<7.5 μg/dL was greater than that observed in those with
a maximal blood lead level of ≥7.5 µg/dL (P=0.015).
These counterintuitive findings might be a product of
residual confounding, falling exposure levels over time
or a decreasing vulnerability for cognitive impairment
with higher age (2). Turning to adults, the literature relating neurocognitive function to lead exposure in studies
of the general population (3–9) or workers (10–13) with
a cross-sectional (3–5, 7, 8, 10), case–control (11, 13) or
longitudinal design (6, 9, 12) is contradictory. Similarly,
two systematic reviews (14, 15), including 22 studies
of exposed and unexposed workers but using different
statistical methods, concluded that there was an inverse
(14) or a null (15) association between neurocognition and occupational lead exposure. Unexposed and
exposed blood lead levels in workers were unavailable
in over ten studies (15). None of the studies compared
blood lead levels before and after exposure (15). None
of the individual studies was conclusive. Lack of true
measures of the pre-occupational exposure and observer
and publication bias were other issues obscuring the
true relation between neurocognitive function and lead
exposure for blood lead levels <70 µg/dL (15). Given
the contradictory results of individual studies (3–13) and
literature reviews (5, 14, 15), we identified a great need
for prospective studies that would account for variability
between people by comparing test results before and
after lead exposure In the Study for Promotion of Health
in Recycling Lead (SPHERL; NCT02243904) (16), we
assessed the association between neurocognitive function and blood lead in young workers prior to (17) and
up to two years after starting first occupational exposure.

Methods
Participants
SPHERL is a longitudinal study of newly hired lead
workers at battery manufacturing and lead recycling
plants in the United States (16). SPHERL complies with
the Helsinki Declaration for investigations in humans
(18). The Ethics Committee of the University Hospitals
Leuven (Belgium) approved the study protocol. The
health of the labor force was protected in compliance
with the US Occupational Safety and Health Administration Standard (www.osha.gov/laws-regs/regulations/
standardnumber/1910/1910.1025), which includes
regular health check-ups, proper workplace ventilation,
and the obligatory use of personal protective equipment.
The two‑year neurocognitive responses to first occupational lead exposure were a predefined secondary study
endpoint (16).
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Of 746 newly hired workers invited to participate,
601 (80.6%) consented. However, in the interval between
consent and the planned baseline examination (median,
19 days; 5–95th percentile interval, 9–59 days), 95 laborers left the workplace or withdrew. From 25 January
2015 until 19 September 2017, 506 workers underwent
the baseline examination, of whom 289 (57.1%) had one
and 236 (46.6%) had two follow-up visits (figure 1). Of
289 participants with at least one follow-up visit, 22
were disqualified for analysis because blood lead had not
been measured at baseline (N=3) or follow-up (N=1),
because both the digit-symbol test (DST) and Stroop
test (ST) had not been administered (N=2), or because
workers were on neuropsychiatric medications (N=16),
including antidepressants, amphetamines, sedatives,
recreational drugs and/or opioids. Of the 267 analyzed
participants, 7 were excluded from the DST cohort,
because of missing baseline DST; 99 were excluded
from the ST cohort, because of missing ST at baseline
(N=2) or follow-up (N=1), missing congruent trials at
follow-up (N=89), or because they had achromatopsia
(N=7). The statistical analysis therefore included 260
participants in the DST cohort and 168 in the ST cohort
with both a baseline and at least one follow-up assessment of their cognitive function and simultaneous blood
lead measurements.
Clinical measurements
At the study sites, trained nurses measured the workers’ anthropometric characteristics and applied current
guidelines to measure office blood pressure at the
brachial artery. After the workers had rested for five
minutes in the sitting position, the nurses obtained five
consecutive blood pressure readings to the nearest 2
mm Hg by auscultation of the Korotkoff sounds, using
standard mercury sphygmomanometers. For analysis,
the five readings were averaged. Blood pressure was
categorized according to the 2017 ACC/AHA guideline (19). If systolic and diastolic blood pressure were
in different categories, the highest value was used to
classify participants. Heart rate was counted over 15
seconds. Body mass index (BMI) was body weight
in kilograms divided by height in meter squared. The
study nurses administered a validated (20) questionnaire at baseline and follow-up to collect information
about each worker’s medical history, exposure to
heavy metals, smoking and drinking habits, intake
of medications, and educational attainment. Alcohol
consumption was categorized as absent, light, moderate or heavy. The thresholds for the daily alcohol
consumption self-reported by questionnaire were ≤6,
>6–14 and >14 gram in women and ≤12, >12–28 and
>28 gram in men.

Yu et al

Figure 1. Flow chart. [BL=blood lead; DST=digit-symbol
test; ST=Stroop test].

Neurocognitive function tests
The neurocognitive examination was conducted in a quiet
air-conditioned room. We administered the computerized version of the DST and ST as published by Xavier
Educational Software Ltd, Bangor, Wales, UK, using a
laptop with touch screen. A video uploaded at the journal’s website illustrates the administration of these tests.
The DST measures processing speed, working
memory, visuospatial processing, and attention (21).
Participants performed the DST test at baseline and
follow-up to assess the impact of lead exposure on
general cognitive functions such as processing speed,
working memory, visuospatial processing, and attention. A row of nine symbols paired vertically with nine
digits was displayed at the top of the computer screen.
The same symbols were also presented at the bottom of
the screen but in a different order. The task is to touch
as fast as possible the symbol at the bottom of the screen
that is paired with the displayed digit. During the test,
36 digits appear one after one in the center of the screen.
The worker performing the test has to provide the correct response before a new digit is presented. The time
needed to complete the test, called latency, and the total
number of errors served as measures of performance.
The ST was used to measure the impact of lead exposure on the Stroop effect, which is related to selective
attention. Workers saw the printed name of a color and
four buttons displayed in yellow, red, blue and green on

the laptop screen. In congruent trials, the name of the
color was printed in the matching color (eg, “yellow” was
printed in yellow). In incongruent trials, the name of the
color was printed in a different color (eg, “yellow” was
printed in red). The task consists of touching the screen
button with the color matching the printed color name
as fast and accurately as possible, ignoring the color of
the printed color name. The ST consisted of 4 congruent
and 12 incongruent trials. Before the test, participants
completed four practice trials. The mean reaction time
(ms) is the average time that passed between the appearance of the color name and touching the correct button in
congruent and incongruent trials, respectively. The main
outcome measure in the Stroop test is the inference effect,
calculated as the ratio of the mean reaction time for the
incongruent to the congruent trials, which is equivalent to
the antilog of the difference between the log transformed
reaction times. The inference score is defined as the proportion of the correct answers in congruent trials minus
the proportion of correct answers in incongruent trials.
Biochemical measurements
Venous blood samples were obtained after 8–12 hours
of fasting. Blood lead levels were determined on whole
blood by inductively coupled plasma mass spectrometry
at an analytical laboratory certified for blood lead analysis in compliance with the provisions of the OSHA Lead
Standard, 29CFR 1910.1025 (Occupational Safety and
Scand J Work Environ Health – online first
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Health Administration [www.osha.gov]). Prior to analysis, the specimens were digested by nitric acid and spiked
with an iridium internal standard. The detection limit was
0.5 µg/dL. The accuracy of the lead tests was verified by
use of proficiency samples purchased from the College
of American Pathologists (CAP) and the Pennsylvania
Department of Blood Lead Programs (22). Proficiency
testing was performed in six separate trial runs, including in total 30 test samples annually. All survey materials
were handled in the same manner as the study samples
and processed with the normal workflow, utilizing the
same repeat/dilution protocols and calibration and quality control frequency (22). Compliance with the Clinical
Laboratory Improvement Amendments (CLIA), CAP and
the New York State accreditation and regulatory requirements was verified routinely with test level review of the
laboratory services by external auditors. Calibrators with
certified accuracy (National Institute of Standards and
Technology [www.nist.gov]) were included in each batch
of study samples and spanned the range of the analytical
measurement range. Accuracy was evaluated by Westgard
Rules (23) and defined within the total allowable error
established with review of the CAP, Centers for Disease
Control and Prevention, CLIA 88 (24), and OSHA guidelines. Accuracy, defined as the deviation from known lead
standards ran along with the study samples, was within
10% (22). The bias determined according to the Bland
& Altman approach (25) in 30 spilt blood samples with
blood lead concentrations (average in duplicate samples)
ranging from 0.70–27.9 µg/dL, was 0.08 µg/dL [95% confidence interval (CI) ‑0.01–0.18, P=0.078; supplementary
material www.sjweh.fi/show_abstract.php?abstract_
id=3940, figure S1) (17). The repeatability coefficient,
defined as twice the SD of the signed differences between
duplicate measurements (25), was 0.52. Expressed as a
percentage of the mean blood lead concentration or as a
percentage of near maximal variation in blood lead (four
times the SD of the logarithmically transformed distribution), the repeatability coefficients were 6.7% and 1.9%,
respectively. Lower values indicate better repeatability.
Serum total and high-density lipoprotein (HDL)
cholesterol, serum creatinine, and blood glucose were
measured by automated enzymatic methods and serum
insulin by ELISA. Over three evaluations, the laboratory obtained a proficiency score of 100% for blood
lead and 100% for routine biochemistry. Diabetes
mellitus was a self-reported diagnosis, a fasting blood
glucose of 126 mg/dL (7.0 mmol/L) or higher, or use
of antidiabetic drugs.
Statistical analysis
For database management and statistical analysis, we
used the SAS software, version 9.4, maintenance level
5 (SAS Institute Inc, Cary, NC, USA). Departure from
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normality was evaluated by the Shapiro-Wilk statistic.
Skewness and kurtosis were computed as the third and
fourth moments about the mean divided by the cube of
the standard deviation. We applied a logarithmic transformation (base 10) to normalize the distributions of
latency time (DST), mean reaction time and interference
effect (ST), and blood lead. We reported the central tendency and spread of continuously distributed variables as
mean with standard deviation (SD) or for logarithmically
transformed variables as geometric mean with interquartile range (IR) or with the 5–95th percentile interval. To
compare means and proportions, we applied the t‑statistic
or ANOVA for continuous variables, and the Fisher exact
test for categorical variables, respectively.
In exploratory analyses, we assessed the results of
DST and ST across fourths of the follow-up-to-baseline
blood lead concentration ratio. Changes in DST and
ST were correlated with the corresponding changes in
log blood lead using a random intercept mixed model,
accounting for the correlations between repeated observations within the same participant. A compound symmetry correlation structure was assumed and variance
parameters were estimated using restricted maximum
likelihood. The model included change in log blood lead
as a fixed effect. Neurocognitive responses to the changes
in blood lead were expressed for a doubling of the followup-to-baseline blood lead concentration ratio. For each
outcome, unadjusted, partially and fully adjusted models
were constructed. Partially adjusted models included sex,
age and the neurocognitive function test at baseline as
covariables. Fully adjusted models additionally accounted
for ethnicity (white versus other), change in age, baseline
BMI, changes in body weight, educational attainment,
baseline blood lead and the baseline values and changes
during follow-up in smoking status, and the total-to-HDL
serum cholesterol, and alcohol consumption (light, moderate and heavy drinkers). Covariables were selected on
the basis of their associations with both neurocognitive
function and blood lead in previous publications (26–29).
In sensitivity analyses, we stratified the study participants
according to median age, the median baseline blood lead
level and the median cumulative blood lead index (CBLI)
(30). We also checked the performance of the mixed
models by relating changes in neurocognitive function
and blood lead separately for the 1‑ and 2‑year visits by
means of linear regression.

Results
Characteristics of participants
Of 260 participants, 229 (88.1%) were men, 122 (46.9%)
were white, 117 (45.0%) were Hispanic, and 21 (8.1%)

Yu et al

had other self-reported ethnicities. At baseline, age
averaged 29.4 years (supplementary figure S2), BMI
28.8 kg/m2, serum creatinine 0.93 mg/dL, total and
HDL serum cholesterol 171.8 mg/dL and 46.8 mg/dL,
the total-to-HDL cholesterol ratio 3.90, and blood glucose 93.8 mg/dL (supplementary table S1). The cohort
included 6 women and 63 men, who were current smokers (N=69; 26.5%); 11 women and 102 men (N=113;
43.4%) reported alcohol intake, of whom 9 and 65, 2
and 23, 0 and 14 were light, moderate and heavy drinkers, respectively. The baseline characteristics of the 168
workers in the ST cohort were similar (supplementary
table S2). The characteristics of 267 workers included in
the DST or ST cohort or both and the 239 workers not
analyzed were largely similar (supplementary table S3).
Blood lead
Median follow-up was 2.0 [5–95th percentage interval
(PI) 1.0–2.2] years. In the DST cohort, the geometric
mean blood lead concentration was 3.97 (PI 0.90–14.3)
μg/dL at baseline, 13.4 (PI 3.70–30.3) μg/dL and 12.8
(PI 2.80–29.2) μg/dL at the first and second follow-up
visits, respectively. The corresponding blood lead levels
in the ST cohort were 4.13 (PI 1.20–13.0) μg/dL, 14.4

(PI 4.60–30.3) μg/dL and 16.1 (PI 5.40–31.5) μg/dL.
The last-follow-up-to-baseline blood lead concentration
ratio averaged 3.30 (PI 0.79–14.9) and 3.44 (PI 1.01–
13.8) in DST and ST cohorts, respectively (figure 2 and
supplementary figure S4). The increase in the blood lead
concentration was fully observed at the 1‑year follow-up
visit (supplementary figure S3).
Digit-symbol test
Workers with a completely correct DST numbered 153
(58.9%) at baseline and 160 (61.5%) at the last followup examinations. Among all participants, the geometric
mean test duration was 108.9 [interquartile range (IQR)
95.8–120.8] seconds at baseline and 107.6 (IQR 91.4–
122.6) seconds at last follow-up. The number of errors
and the mean latency time were similar at baseline and
last follow-up (table 1). Across fourths of the distribution of blood lead changes, trends in baseline (P≥0.076;
supplementary table S4), follow-up (P≥0.38; supplementary table S5) and the longitudinal changes (P≥0.079;
table 2) of errors and of the mean latency time were
not significant. In mixed models (supplementary figure
S5) only accounting for clustering within participants
(P=0.0033; table 3) and in partially adjusted models

Figure 2. Baseline-to-last-follow-up ratios
(D) in blood lead [A, B], latency time in the
digit-symbol test in DST cohort [A], and
mean reaction time in the incongruent
trials in ST cohort [B]. [DST=digit-symbol
test; ST=Stroop test]. Numbers at the right
side of the line graphs represent the mean
ratio (above the unity line) and its SE (below
the unity line). Percentage values represent
the number of workers with a ratio greater
tor kower than unity.
Scand J Work Environ Health – online first
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Table 1. Baseline and follow-up neurocognitive tests in the digit-symbol test (DST) and Stroop test (ST) cohorts. Average values are geometric means
[interquartile range (IQR)]. [CI=95% confidence interval; MRT=mean reaction time].
Characteristic

Baseline
N (%)

DST cohort (N=260)
Mean latency time (s, log)
Number of errors
0
1
>1
ST cohort (N=168)
MRT in incongruent trials (ms, log)
All responses
Correct responses b
MRT in congruent trials (ms, log)
All responses
Correct responses b
Correct ratio in incongruent trials (%)
100
90–99
<90
Correct ratio in congruent trials (%)
100
<100
Interference effect (log)
All responses
Correct responses b
Interference score
<0
0
>0
a

b

Mean (IQR)

Follow-up
N (%)

108.9 (95.8–120.8)
153 (58.9)
73 (28.1)
34 (13.1)

∆ (95% CI) a

P-value

Mean (IQR)

Mean

95% CI

107.6 (91.4–122.6)

-1.17

4.11–1.86

0.44

2.69
-0.77
-1.92

–5.27–10.6
–8.68–7.15
–7.25–3.43

0.74

160 (61.5)
71 (27.3)
29 (11.2)
1606 (1309–1917)
1608 (1307–1922)

2088 (1666–2525)
2077 (1636–2535)

30.1
29.8

22.7–37.9
22.3–37.8

<0.0001
<0.0001

1485 (1181–1714)
1485 (1181–1714)

1979 (1563–2458)
1990 (1574–2476)

33.3
34.0

24.4–42.8
25.0–43.6

<0.0001
<0.0001

145 (86.3)
12 (7.14)
11 (6.55)

138 (82.1)
17 (10.1)
13 (7.74)

-4.17
2.98
1.19

–11.8–3.59
–3.25–9.13
–3.98–6.33

0.55

168 (100.0)
0 (0.0)

164 (97.6)
4 (2.38)

-2.38
2.38

–5.15–0.45
–0.45–5.15

0.044

-2.40
-3.08

–7.36–2.82
–8.24–2.37

0.36
0.26

1.79
-5.36
3.57

–0.80–4.33
–13.2–2.57
–4.10–11.2

0.14

1.08 (0.96–1.21)
1.08 (0.97–1.21)
0 (0.00)
145 (86.3)
23 (13.7)

1.06 (0.90–1.22)
1.05 (0.87–1.22)
3 (1.79)
136 (80.9)
29 (17.3)

Changes from baseline to last follow-up were given with 95% CI. For proportions, categorical variables and logarthmically transformed variables, percentage
changes are given.
One participant did not provide any correct response at baseline and follow-up and was not included in the MRT of correct responses.

(P=0.040) also adjusted for sex, age and the baseline
test result, the change in latency time increased with
the follow-up-to-baseline blood lead concentration ratio.
However, in a fully adjusted model, this association size
weakened to 0.55% (95% CI ‑0.33–1.42; P=0.22; table 3
and supplementary figure S5). Moreover, in unadjusted,
partially adjusted and fully adjusted model, none of the
odd ratios for an increasing error rate reached significance (P≥0.12; table 3).
We ran stratified analyses using fully adjusted models to evaluate the consistency of the changes of neurocognitive function among workers aged <26.4 and
≥26.4 years (supplementary table S6), baseline blood
lead <4.20 and ≥4.20 μg/dL (supplementary table S7),
and CBLI <32.5 and ≥32.5 μg/dL × year (supplementary table S8), respectively. In these stratified analyses,
an increasing error rate in the high baseline blood lead
subgroup was the only measurement, which tended to
be associated with the follow-up-to-baseline blood lead
concentration ratio: odds ratio, 1.68 (95% CI 0.99–2.86;
P=0.056 in the high baseline blood lead stratum vs 1.00
in the low exposure group (95% CI 0.64–1.58; P=0.99)
with a nonsignificant interaction (P=0.34; supplementary
table S7). The results of the linear regression analyses
correlating changes in latency time and blood lead
separately at the 1‑ and 2‑year follow-up visits largely
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confirmed the findings obtained by mixed models (supplementary table S9).
Stroop test
The Stroop test with incongruent trials was completed
error free in 145 (86.3%) workers at baseline, with no
difference between baseline and follow-up in these proportions (P=0.55; table 1). The mean reaction time for
incongruent trials increased from 1606 ms at baseline to
2088 ms at the last follow-up visit in all participants and
from 1608 ms to 2077 ms, if only the correct responses
were considered (P<0.0001). The changes from baseline
to follow-up averaged 30.1% (CI 22.7–37.9; P<0.0001)
and 29.8% (CI 22.3–37.8; P<0.0001), respectively (table
1). Supplementary tables S11 and S12 show the mean
reaction time and blood lead levels at baseline and
follow-up, and overall, in the workers tested and broken down by the attending observer. Supplementary
table S11 illustrates the effect of the observer on test
performance and supplementary table S12 reflects the
unpaired distribution of observers between the baseline
and follow-up examinations.
Across fourths of the distribution of the blood lead
changes, there was a trend towards smaller increases in
mean reaction time with larger increases in blood lead

Yu et al

Table 2. Changes (∆) from baseline to follow-up in the neurocognitive responses by fourths of the distribution of follow-up-to-baseline blood lead
concentration ratio. [PI=5–95th percentile interval; DST=digit-symbol test; ST=Stroop test; MRT=mean reaction time].
Characteristic a

Low fourth
Mean/
Median

Low-middle fourth
PI

Mean/
Median

PI

High-middle fourth
Mean/
Median

PI

High fourth
Mean/
Median

PI

P for linear
trend

DST cohort (N=260)
Quartile limits
<1.90
1.90-3.37
3.37-5.75
>5.75
∆ latency time (%)
-7.06
-41.7–43.8
1.59
-30.3–51.6
-0.28
-33.9–42.5
1.33
-27.6–38.7
∆ number of errors
0.0
-2.0–1.0
0.0
-3.0–2.0
0.0
-1.0–2.0
0.0
-1.0–1.0
ST cohort (N=168)
Quartile limits
<1.98
1.98-3.26
3.26-5.52
>5.52
∆ MRT in incongruent trials
All responses (%)
39.9
-9.32–169
35.0
-25.7–162
33.7
-25.8–102
13.4
-28.2–160
Correct responses (%) b
42.4
-6.09–175
34.6
-25.7–162
35.3
-25.8–102
9.32
-31.5–159
∆ MRT in congruent trials
All responses (%)
49.6
-19.8–231
35.5
-23.7–158
23.7
-33.7–128
25.8
-34.6–175
Correct responses (%) b
49.6
-19.8–231
36.9
-23.7–158
23.7
-33.7–128
27.3
-34.6–175
∆ number of errors in incongruent trials
0.0
-1.0–1.0
0.0
-2.0–5.0
0.0
-1.0–2.0
0.0
-1.0–1.0
∆ number of errors in congruent trials
0.0
-0.0–0.0
0.0
-0.0–0.0
0.0
-0.0–0.0
0.0
-0.0–0.0
∆ interference effect
All responses (%)
-6.53
-37.1–37.9
-0.38
-41.5–84.6
8.12
-32.6–71.2
-9.88
-46.1–70.7
Correct responses (%) b
-5.80
-36.8–45.1
-2.40
-43.8–79.5
9.42
-31.3–90.4
-12.8
-51.8–83.1
a Values are geometric means (reported as percent change) and PI for logarithmically transformed variables, and median and PI for ordinal variables.
b One participant did not provide any correct response at baseline and follow-up and was not included in the MRT of correct responses.

0.079
0.13

0.015
0.0037
0.051
0.061
0.34
0.37
0.91
0.65

Table 3. Associations between changes (∆) from baseline to follow-up in neurocognitive function and in blood lead. [OR=odds ratio; CI=confidence
interval; DST=digit-symbol test; ST=Stroop test].
Characteristic

Unadjusted
%c

DST cohort (N=260)
∆ latency time (%)
Increasing error rate (0,1)
ST cohort (N=168)
∆ MRT in incongruent trials
All responses (%)
Correct responses (%) d
∆ MRT in congruent trials
All responses (%)
Correct responses (%) d
Increasing error rate e
Incongruent trials (0,1)
Congruent trials (0,1)
∆ Interference effect
All responses (%)
Correct responses (%)

Adjusted a

OR c

95% CI

1.04

0.39–1.95
0.87–1.25

0.0033
0.65

0.66

-2.03
-2.65

-3.91–-0.11
-4.55–-0.70

0.039
0.0092

-1.57
-1.55

-3.85–0.76
-3.83–0.79

0.18
0.19

0.54–1.07
0.55–2.87

0.11
0.59

-2.16–1.33
-2.52–1.14

0.62
0.44

1.17

0.76
1.25
-0.43
-0.71

P-value

%c

Fully adjusted b

OR c

95% CI

1.00

0.03–1.30
0.83–1.21

0.040
0.96

0.55

-1.95
-2.23

-3.48–-0.39
-3.76–-0.68

0.016
0.0061

-1.64
-1.61

-3.41–0.15
-3.37–0.18

0.072
0.077

0.50–1.04

0.078

-1.63–0.94
-1.76–0.87

0.59
0.49

0.72
-0.35
-0.45

P-value

%c

OR c

95% CI

P-value

-0.33–1.42
0.94–1.76

0.22
0.12

-0.83
-1.26

-3.20–1.59
-3.59–1.13

0.49
0.29

-1.56
-1.54

-4.32–1.28
-4.29–1.30

0.27
0.28

1.08
1.05

-0.97–3.17
-1.03–3.17

0.29
0.32

1.28

Adjusted models accounted for sex and baseline age and the baseline neurocognitive test results, ie, latency/reaction time (continuous outcomes) or the number of
errors (ordinal outcomes).
b Fully adjusted models additionally accounted for ethnicity (white vs other), change in age, baseline body mass index, change in body weight, educational attainment, baseline blood lead, and the baseline values of and changes during follow-up in smoking status, alcohol intake (light, moderate and heavy), and the totaltoHDL serum cholesterol ratio.
c All association sizes were expressed for a doubling of the baseline-to-follow-up blood lead concentration ratio. Estimates are the percentage difference in the follow-up minus the baseline value for continuous variables and odds ratios for categorical outcomes. Estimates were derived from mixed models, including both the
1-year and 2-year changes in neurocognitive function and blood lead, while accounting for within-subject correlations using a random participant effect.
d One participant did not provide any correct response at baseline and follow-up and was not included in the MRT of correct responses.
e An ellipsis indicates that the model did not converge.
a

(P≤0.015; table 2). For congruent trials, 168 (100%)
were completed with fully correct answers at baseline
and 164 (97.6%) at follow-up visit with an increasing
mean reaction time from 1485 ms to 1979 ms (P<0.0001,
table 1). The geometric means of the interference effects
were 1.08 at baseline and 1.06 at the last follow-up visit
in all workers. The distributions of inference score were
similar at baseline and last follow-up visits (P=0.14;
table 1). For congruent trials, in unadjusted and in

partially and fully adjusted models, irrespective of
whether all trials or only the error-free trials were analyzed, there was no association between the changes in
mean reaction time and those in blood lead (P≥0.072;
table 3). For incongruent trails, in the unadjusted models only accounting for clustering within participants
and in the partially adjusted models, the longitudinal
change in mean reaction time decreased as the blood
lead increasing. However, in the fully adjusted models,
Scand J Work Environ Health – online first
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the association sizes for a doubling of blood lead were
‑0.83% (95% CI ‑3.20–1.59; P=0.49) in all trials and
‑1.26% (95% CI ‑3.59–1.13; P=0.29) in error-free trials, respectively (table 3 and supplementary figure S5).
Moreover, there was no association between the changes
in interference effect and those in blood lead (P≥0.29;
table 3). In the analyses stratified by median age (27.0
years; supplementary table S5), median baseline blood
lead (4.30 μg/dL; supplementary table S6), or median
CBLI (33.3 μg/dL × year; supplementary table S7), associations were all nonsignificant (P≥0.096; interaction
P≥0.22). Linear regression analysis of the 1-year data
was confirmatory (supplementary table S9).
Consistency between baseline and last follow-up data
Supplementary table S10 lists the associations between
blood lead level and the performance of participants in
the neurocognitive tests at baseline and the last followup separately. None of the association sizes (slopes) in
unadjusted or adjusted analyses reached significance
(P≥0.14), with no differences between baseline and last
follow-up in the association sizes (P slope≥0.23).

Discussion
In a real-world experiment, among workers without
known previous occupational exposure and taking up
new jobs in lead recycling and battery manufacturing
plants in the United States, an over threefold increase in
the blood lead concentration over the 2‑year follow-up
was not associated with worsening of cognitive function,
as assessed by the DST and ST. These longitudinal findings are in keeping with the cross-sectional analysis of
the baseline SPHERL data (supplementary table S10),
which did not show any association between cognitive
performance as assessed by the same tests and blood
lead prior to occupational exposure (17). The longitudinal changes in mean reaction time in incongruent ST trials tended to correlate inversely with the corresponding
changes in blood lead, similar to congruent trials (tables
2 and 3). To what extent training effects (31) or the interaction between observers and test takers (supplementary
table S11) influenced the ST test performance cannot
be ascertained. To exclude an effect of the cumulative
lead dose, we ran analyses stratified by the medians of
age, baseline blood lead or CBLI in both cohorts, which
confirmed the main analysis.
Lead is a cumulative toxicant, which is for 90–95%
stored in bone, from where it is recirculated with a
half-life of 20–25 years (32, 33). Blood lead, for 95%
carried by red blood cells, reflects recent exposure over
the past 1–2 months and the amount of lead released
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and recirculated from bone (32). Bone lead correlates
with blood lead (33, 34) and explains around 20% of
the variance in blood lead, depending on seasonality
(33) and hormonal and other endogenous and environmental stimuli, influencing the balance between
bone formation and resorption (34). Recirculation of
lead from bone explains why there is a lag time when
occupational (32) or environmental (35) lead exposure
drops. These lead toxicokinetics are important in the
interpretation of our current results. A narrative review
on the association of neurocognitive function and lead
exposure compiled evidence from 21 studies published
from 1996–2006. All studies had assessed bone and
blood lead as biomarkers of internal exposure, 15 in
occupational studies and 6 in environmental settings
(5). At exposure levels representative of contemporary
environmental exposure, associations of cognitive function with biomarkers of cumulative dose (mainly lead in
tibia) were stronger and more consistent than associations with blood lead levels as assessed by concurrent,
cumulative or peak blood lead levels (36). Conversely,
studies of currently exposed workers generally found
associations that were more apparent with blood lead
levels (36). Given the persistence of lead in the human
body, both bone and blood lead increase with advancing age (33, 34). Consequently, with advancing age,
the blood lead concentration reflects environmental
exposure levels stretching further back in time. In the
United States (scienceprogress.org/2008/10/a-briefhistory-of-lead-regulation), lead-containing paint was
only effectively banned in 1976 and leaded gasoline was
completely phased out only in 1995 (37). Mean blood
lead levels in the United States decreased from 13.1 μg/
dL in the National Health and Nutrition Examination
Survey II (NHANES II; 1976–1980) (38) to 2.76 μg/dL
in NHANES III (1988–1994) (39) and to 1.64 μg/dL in
NHANES IV (1999–2002) (28). Our study moves the
field forward because the cumulative lead dose in our
young participants must reflect present-day environmental exposure levels and, as suggested in a systematic
literature review (15), we addressed variability between
people by comparing neurocognitive test results before
and after occupational exposure.
Neurocognitive functions are integrated cognitive
processes linked to multiple particular cerebral areas,
neural pathways or cortical networks in the brain (40,
41). In this study, we evaluated the neurocognitive function, using two complementary tests, which are sensitive
to detect mild cognitive impairment under lead exposure
(31, 42). On the one hand, the DST assesses complex
attention, motor speed, visual-perceptual functions and
executive function (42). Functional magnetic resonance
imaging (fMRI) studies in young healthy adults (43)
and octogenarians (44) showed that taking the DST
activated the frontal parietal cortical network, probably
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reflecting visual search and working memory processes
(43, 44). The ST provides information on processing
speed, selective attention, automaticity and parallel
distributed processing (45–47). In fMRI studies, taking
the ST activated the anterior cingulate, insula, premotor
and inferior frontal brain regions (48).
Strengths and limitations
The strong points of our study are its longitudinal
design (15), the young age of its participants the starting
blood lead level representative of current environmental
exposure levels, and the stringent quality control of
the blood lead concentration. However, our study also
has limitations. First, the attrition rate among the 506
workers who participated in the baseline examination,
but defaulted from follow-up amounted to 217 (42.9%).
However, according to the SPHERL protocol (16), the
anticipated attrition rate was estimated to be 50% and
>500 workers had to be enrolled. We met these numbers.
The baseline characteristics of workers included or not
included in the analyses were to a large extent similar
(supplementary table S3), so that it is unlikely that attrition significantly biased the study results, although bias
due to unmeasured confounders can never be excluded.
Second, the study was primarily powered for blood
pressure and renal outcomes, while neurocognitive
function was among the secondary outcomes. However, the association sizes between the changes in the
neurocognitive indexes and blood lead were small and
sample size does impact on significance levels, but has
no direct link with estimates of association size. Third,
due to a software error, the ST with congruent trails
was only administered to 168 (62.9%) participants at
follow-up. However, the results of the congruent and
incongruent tests were consistent. Fourth, the observerparticipant pairing was not standardized throughout the
study (supplementary tables S11 and table S12), which
might have introduced bias in the observed baseline to
follow-up changes in neurocognitive function. Fifth, the
median 2‑year follow-up might have been too short for
neurocognitive effects associated with lead exposure to
become evident. For this reason, as anticipated (16) the
cohort will be kept in follow-up for an additional two
years. Finally, although the ethnic distribution of the
workers was representative for the population at the
recruitment sites, women were under-represented. Only
11.6% of 267 analyzed participants were female, which
precluded analyses stratified by sex.
Concluding remarks
At the exposure level in our study, we failed to demonstrate a consistent and significant association of changes
in neurocognitive function in the workers with an over

threefold increasing blood lead concentration over the
2‑year follow-up. Lead exposure represents an occupational and environmental health hazard that should be
addressed worldwide. Our findings and the contradictory
literature (15) suggest that in adults there is no causal
link between neurocognitive impairment and low-level
lead exposure as reflected by blood lead levels below
30 µg/dL. In weight-of-the-evidence approaches, policy
makers might account for our findings in setting thresholds for occupational and environmental lead exposure
levels, so that the prevention resources of neurocognitive function are dedicated to the more important drivers
of cognitive impairment, in particular low educational
attainment, socio-economic deprivation, abuse of alcohol and recreational drugs, discriminating based on ethnicity, and not providing opportunities for immigrants to
assimilate the skills necessary for social integration (29).
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